Exciting news: The UK is currently conducting a vital trial for the world’s first “personalised” mRNA vaccine, targeting the deadliest form of skin cancer – melanoma.

The introduction of mRNA 4157 (v940) marks a significant advancement in cancer treatment, leveraging the same cutting-edge technology employed in COVID vaccinations. This innovative approach aims to empower the immune system to identify and eliminate any lingering cancerous cells, offering hope for more effective cancer therapies.

Doctors at University College London Hospitals (UCLH) are administering this alongside another drug, pembrolizumab or Keytruda, which also aids the immune system in targeting and destroying cancer cells.

It is crucial to emphasize that the treatment developed by Moderna and Merck Sharp and Dohme (MSD) is not currently available as a standard option within the NHS, except for participation in phase III clinical trials.

Experts in several other countries, such as Australia, are also conducting trials on patients to accumulate further evidence and determine whether it warrants broader implementation.

The vaccine is customised to accommodate each individual patient, tailoring its composition to suit their specific needs.

The treatment is designed to align with the individual genetic profile of the patient’s tumor. It functions by directing the body to produce proteins or antibodies that target specific markers or antigens present exclusively on those cancerous cells.

The UK part of the international trial is a crucial and ambitious initiative focused on recruiting at least 60-70 patients across eight prominent centres. These centres are located in London, Manchester, Edinburgh, and Leeds, representing a widespread effort to contribute to the advancement of medical research and the improvement of patient care. This collaborative effort underscores the dedication and commitment of the medical community to enhancing healthcare outcomes on a global scale, reinforcing the importance of accessible and innovative treatments for patients around the world.

Patients who are participating in the clinical trial are required to have undergone surgical removal of their high-risk melanoma within the preceding 12 weeks. This parameter is crucial in ensuring the optimal outcome for the trial and maintaining consistency in the evaluation process. By specifying this timeframe, the trial aims to assess the impact of the treatment with a focus on recent surgical interventions, thereby contributing to a comprehensive understanding of the potential benefits for this specific patient group.

The Phase II trial data, published in December, provided a significant breakthrough in the treatment of serious high-risk melanomas. The remarkable findings revealed that individuals who received the jab alongside the immunotherapy Keytruda demonstrated a noteworthy trend. Specifically, they were observed to be almost half (49%) as likely to experience mortality or cancer recurrence within the span of three years compared to those who solely received the drug. This promising outcome marks a pivotal advancement in the ongoing efforts to enhance the effectiveness of treatments for high-risk melanomas, offering renewed hope to patients and medical professionals alike.

This development is absolutely thrilling, occurring in tandem with immunotherapy treatment, and has the potential to revolutionize the outlook for melanoma patients in the years ahead.

I’m glad I had the opportunity to participate in the BBC Radio 2 show hosted by Jeremy Vine, where the discussion revolved around the personalised vaccine. It’s an important topic that impacts many people, and my involvement in this conversation was valuable. Sharing the link to the recording of that part of the show adds an extra layer of depth to my experience, allowing others to engage with the discussion and learn from it. Simply click on the picture below to listen to the recording.